Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03868345 · ClinicalTrials.gov registry record

Speech Analysis in ALS Patients

A clinical trial, sponsored by Barrow Neurological Institute.

Completed
Registry status
26
Enrollment target

NCT03868345 is a clinical trial that has completed, run by Barrow Neurological Institute. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03868345 has completed, sponsored by Barrow Neurological Institute.

COMPLETED
Registry status
26 participants
Enrollment target

Study Summary

The purpose of this study is to find out if changes in speech can signal changes in the ability to think or remember. ALS patients with and without cognitive dysfunction will be followed for one year. Every three months, patients will undergo a series of cognitive and basic clinical outcomes tests. In addition, participants will take home a study-provided tablet on which they will complete weekly speech recording activities.

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2019-02-18
Est. Completion 2021-04-30

Sponsor

Barrow Neurological Institute

4 total trials

What the Registry Record Tells You About NCT03868345

The ClinicalTrials.gov registry entry for NCT03868345 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barrow Neurological Institute, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT03868345 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03868345 about?

NCT03868345 is a clinical study titled "Speech Analysis in ALS Patients". The purpose of this study is to find out if changes in speech can signal changes in the ability to think or remember. ALS patients with and without cognitive dysfunction will be followed for one year. Every three months, patients will undergo a series of cognitive and basic clinical outcomes tests. ...

What is the current status of trial NCT03868345?

This trial is currently completed. The enrollment target is 26 participants. The study started on 2019-02-18. Estimated completion is 2021-04-30.

Who is sponsoring clinical trial NCT03868345?

This trial is sponsored by Barrow Neurological Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.